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Background: The influence of natural regulatory T cells (nTregs) on the patients with colon cancer is unclear.
Demethylated status of the Treg-specific demethylated region (TSDR) of the FOXP3 gene was reported to be a
potential biomarker for the identification of nTregs.
Methods: The demethylation rate of the TSDR (TSDR-DMR) was calculated by using methylation-specific quantitative
polymerase chain reaction (MS-qPCR) assay. The expression of TSDR-DMR and FOXP3 mRNA was investigated in various
colorectal cancer cell lines. A total of 130 colon carcinoma samples were utilized to study the DMR at tumor sites
(DMRT) and adjacent normal tissue (DMRN). The correlations between DMRs and clinicopathological variables of
patients with colon cancer were studied.
Results: The TSDR-DMRs varied dramatically among nTregs (97.920 ± 0.466%) and iTregs (3.917 ± 0.750%). Significantly,
DMRT (3.296 ± 0.213%) was higher than DMRN (1.605 ± 0.146%) (n = 130, p = 0.000). Higher DMRN levels were found in
female patients (p = 0.001) and those with distant metastases (p = 0.017), and were also associated with worse
recurrence-free survival in non-stage IV patients (low vs. high, p = 0.022). However, further Cox multivariate analysis
revealed that the FOXP3-TSDR status does not have prognostic value.
Conclusion: MS-qPCR assays of FOXP3-TSDR can efficiently distinguish nTregs from non-nTregs. Abnormal recruitment
of nTregs occurs in the local tumor microenvironment. Infiltration of tissue-resident nTregs may have a negative role in
anti-tumor effects in patients with colon cancer; however, this role is limited and complicated.
Keywords: Regulatory T cells, Colorectal cancer, Transcription factor forkhead box P3, Treg-specific demethylated
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Colorectal cancer (CRC) is one of the most prevalent
life-threatening malignancies, ranking as the third most
frequently diagnosed cancer and the second leading
cause of cancer death in the United States [1]. Although
survival depends mainly on the stage at diagnosis [2,3],* Correspondence: caisanjun@gmail.com; binli@sibs.ac.cn
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CRC is the modulation of the immune system [4].
Regulatory T cells (Tregs) are essential for maintaining
self-tolerance [5,6]. The transcription factor forkhead
box P3 (FOXP3) is regarded as a critical developmental
and functional factor for CD4 + CD25+ Tregs [5,7,8]. In
humans, however, FOXP3 is not expressed exclusively in
natural Tregs (nTregs) [9-13]. Recently, it was shown
that the Treg-specific demethylated region (TSDR) is
significantly demethylated in human nTregs, while it is
completely methylated in induced Tregs (iTregs) and
other non-suppressive T cells that also express FOXP3
[14,15]. TSDR is a CpG dinucleotide-rich and highly con-
served region within the conserved non-coding sequencestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Demethylation in TSDR is thought to contribute to both
the stability of FOXP3 expression and the maintenance of
the suppressive phenotype for nTregs [16]. FOXP3 in-
duction by TGF-β is associated with only partial or no
demethylation of the TSDR, an unstable state that is re-
versed upon restimulation [15,17].
At present, the exact quantification methods of human
Tregs, which are based on the expression of the FOXP3
protein, are technically demanding and error-prone, and
interpretation of the results can be ambiguous and sub-
jective [4,10]. These methods include tissue microarrays
(TMA), immunohistochemistry (IHC), and flow cytome-
try (FCM). Moreover, it is impossible to differentiate
nTregs from non-Treg cells using these traditional
methods. A methylation-specific quantitative polymerase
chain reaction (MS-qPCR) assay was recently developed
to quantify the proportion of demethylated FOXP3-TSDR
in the peripheral blood as well as in solid tissue samples in
various diseases, and it was regarded as a potential bio-
marker for the identification of nTregs [4,14,15,17-21].
Tregs are considered to be a major cell population
involved in tumor immune tolerance [22]. Elevated pro-
portions of Tregs infiltrating the tumor nests or in the
peripheral blood have been described in several neo-
plasms; and generally, this appeared to be associated
with unfavorable clinical outcomes [23-26]. In patients
with CRC, however, there have been several discordant
results on the prognostic value of Treg infiltration,
which might play a negative [27-30] or positive [31-34]
role in combating cancer. The influence of nTregs, the
most important subset of Tregs, on the survival out-
comes of patients with CRC remains unclear.
In this study, we aimed to investigate the correlation
between the demethylation status of FOXP3-TSDR and
the clinicopathological features of Chinese patients with
colon cancer. We determined that the established MS-
qPCR system could function well in identification of
nTregs from non-nTregs. Our data indicated that nTregs
might have a negative role in anti-tumor effects, although
their impacts on the survival outcomes of patients with
colon cancer may be limited and complicated.Results
The MS-qPCR system could efficiently differentiate nTregs
from non-nTregs using the FOXP3-TSDR demethylation
assay
Human CD4+CD25+CD127lo nTregs and CD4+CD25−
CD45RA+ naïve T cells from a male donor were purified
after separation from peripheral blood mononuclear cells
(PBMCs) by fluorescence-activated cell sorting (FACS),
and iTregs were differentiated from the population of
naïve T cells (Figure 1A). Both the nTregs and iTregswere expanded in vitro, achieving a cell purity of more
than 93% (Figure 1B).
To verify whether the primer sets functioned properly,
we quantitatively analyzed the demethylation rates (DMR)
of TSDR in nTregs and iTregs. The amplification products
were verified by DNA sequencing. The TSDR-DMR varied
dramatically among nTregs (97.920 ± 0.466%) and iTregs
(3.917 ± 0.750%) (Figure 1C). The ideal 100% and 0%
TSDR-DMR could not be achieved for nTregs and non-
nTregs, respectively, due to the cell purities mentioned
above. Our data confirmed that the MS-qPCR assay
coupled with the specific primer sets could efficiently dis-
tinguish FOXP3+ nTregs from non-nTregs.
CRC cell Lines exhibit low levels of demethylated
FOXP3-TSDR
We investigated the TSDR-DMR among various cell lines.
Among HEK 293T cells, which do not express FOXP3
and thus served as negative controls here, an extremely
low DMR (1.484 ± 0.579%) was documented. When com-
pared to nTregs, an extremely low DMR was also detected
among CRC cell lines, ranging from a mean of 0.974% (for
Colo-320) to a mean of 4.003% (for LS-174T) (Figure 2A).
Compared to its level in nTregs, extremely low levels of
FOXP3 mRNA expression (Figure 2B) and undetectable
protein expression (data not shown) were consistently de-
tected among HEK 293T and CRC cell lines. These results
reinforced the notion that CRC cells barely express this
biomarker and make a very limited contribution to the
overall demethylation status in tumor tissues.
Analysis of the FOXP3-TSDR demethylation status in
solid tissue samples revealed abnormal recruitment and
predominant enrichment of nTregs in the tumor
microenvironment
Next, we evaluated the demethylation status of solid tissue
samples obtained from patients with colon cancer. For a
specific patient, compared to the corresponding adjacent
normal tissues, tumor tissues contain the altered propor-
tion of nTregs aside from the extra malignant cells. Be-
cause CRC cells scarcely express this epigenetic marker
for nTregs (as described above), the evaluation of the gen-
eral FOXP3-TSDR demethylation status in the tissue sam-
ple by MS-qPCR can reveal the density of nTregs within
the parenchymal tissue in each sample.
Overall, a significantly higher TSDR-DMR was found in
tumor sites versus normal sites (3.296 ± 0.213% vs. 1.605 ±
0.146%, n = 130, p = 0.000; Figure 3A). Furthermore, there
existed significantly more FOXP3 mRNA expression
(8.454 vs. 1.000, n = 21, p = 0.003; Figure 3B) and higher
protein synthesis in tumor tissues (see the representative
differential expression of mRNA and protein shown by
Figure 3C and Figure 3D). It implied that more Tregs ac-
cumulate in tumor nests than that in adjacent normal
Figure 1 Purification of nTregs and iTregs from PBMCs and their identification using FOXP3-TSDR demethylation-specific qPCR assays.
(A) Purification of CD4+CD25+CD127lo nTregs (bottom right) and CD4+CD25−CD45RA+ naïve T cells (upper right) by FACS after separation from PBMCs
obtained from a male donor. (B) Representative analysis of the cell purities of FOXP3+ cells in nTregs (93.7%, lower panel) and iTregs (97.2%, upper
panel) purified from a CD4+ CD25+ T cell subset by FACS after Treg expansion in vitro. As indicated with black arrows, populations of unstained cells
and cells containing IL-2 beads were used as the controls for the quantification of nTregs and iTregs, respectively. (C) The demethylation rates of
FOXP3-TSDR varied dramatically between nTregs and iTregs, and the specific primer sets were verified in quantitative real-time PCR.
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response, occurring mainly in tumor nests, is caused by
the tissue-resident lymphocytes, including effector T cells
and suppressive Tregs. Of the latter ones, nTregs were ab-
normally recruited and predominantly enriched within
tumor microenvironment.Figure 2 CRC cell lines express very low levels of demethylated FOXP
FOXP3 mRNA, served as negative controls. (A) Compared to nTregs, CRC ce
MS-qPCR assay. (B) Extremely low levels of FOXP3 mRNA expression were o
real-time RT-PCR assay.The FOXP3-TSDR DMR was higher in normal tissues in
female patients and those with distant metastases
Next, we investigated the associations between FOXP3-
TSDR demethylation levels and the clinicopathological
variables in the included patients. In addition to DMRT
and DMRN, the relative demethylation level in paired3-TSDR and FOXP3 mRNA. HEK 293T cells, which do not express
ll lines showed lower levels of demethylated FOXP3-TSDR based on an
bserved among CRC cell lines when compared to nTregs based on a
Figure 3 TSDR-DMR, expression levels of FOXP3 mRNA and protein in tissue samples. (A) Significantly higher TSDR-DMR in tumor samples
versus normal samples, as investigated by MS-qPCR (p = 0.000, n = 130). (B) Significantly higher FOXP3 mRNA expression in samples of tumor tissues
versus samples of normal tissues, as detected by real-time RT-PCR (p = 0.003, n = 21). The Wilcoxon matched pairs test was applied to both (A) and
(B) because the data were not normally distributed. A two-tailed p value ≤0.05 was considered statistically significant. (C) Representative results
showing higher FOXP3 mRNA expression in tumor tissues versus normal tissues, as detected by agarose gel electrophoresis (p = 0.009, n = 5). RT-PCR
products of target (FOXP3) and internal control (β-actin) gene were loaded in two rows of parallel lanes and electrophoreses were performed
simultaneously. DL500 was served as a DNA marker. (D) Representative result showing increased FOXP3 protein synthesis in tumor tissues versus
normal tissues, as detected by Western blotting (p = 0.039, n = 4). For both (C) and (D), ImageJ software was used to perform quantitative analysis of
the densities of band, and paired t tests were applied. A two-tailed p value ≤0.05 was considered statistically significant.
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colonic tissue (DMRT/DMRN) was also calculated for
each patient.
Significantly, higher TSDR-DMR levels in normal tissues
(DMRN) were found among female patients (p = 0.001)
and those who had distant metastases (M1) (p = 0.017).
Similarly, trends of higher DMR levels were also found in
these two groups of patients according to DMRT, althoughthe differences were not significant (p = 0.122 for Gender,
and p = 0.865 for Distant metastases) (Figure 4). The rela-
tive demethylation levels (DMRT/DMRN), however, turned
out to be significantly opposite to the results mentioned
above (higher for male patients and those without distant
metastases (M0), p = 0.003 and 0.037, respectively
(Table 1). Other clinicopathological variables were also in-
vestigated; however, none were associated with the
Figure 4 Certain clinicopathological features were associated with the demethylation status of FOXP3-TSDR in tissue samples.
Associations between DMRs and Gender and Distant metastasis (M) were shown. A higher TSDR-DMR was detected in normal tissues (DMRN)
both in female patients (p = 0.001, Figure 4B) and those with distant metastases (M1) (p = 0.017, Figure 4D). Either for Gender or for Distant
metastasis, no correlation was found to be with the TSDR-DMR in tumor nests (DMRT) (Figure 4A, 4C). Mann-Whitney U tests were applied, and a
two-tailed p value ≤0.05 was considered statistically significant.
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here implied that nTregs in adjacent normal tissues might
have a negative effect on the anti-tumor response.
Clinical survival analysis revealed that non-stage IV
patients with higher TSDR-DMR in normal Tissues (DMRN)
had worse recurrence-free survival
We next analyzed the clinical survival outcomes, includ-
ing overall survival (OS) and recurrence-free survival
(RFS), according to DMRT and DMRN as well as DMRT/
DMRN. Overall, the patients completed a median follow-
up of 54.5 (3-71) months. When compared to patients
with higher TSDR-DMRs (either DMRT or DMRN), pa-
tients with lower demethylation rates had better OS and
RFS as well as a longer median survival time (Figure 5;
also see Additional file 1: Tables S1 and Additional file 2:
Table S2). Overall comparisons performed with log-rank
tests revealed that the difference was significant only for
RFS according to the variable DMRN (low vs. high, p =
0.022, Figure 5E). This result implied that a high propor-
tion (density) of nTregs infiltrating adjacent normal tis-
sues other than malignant nests was associated with
worse survival outcomes in patients with non-stage IV
colon cancer.
Cox correlation analysis revealed that FOXP3-TSDR DMR
levels were not independent prognostic factor
To investigate the prognostic variables that can predict
the overall or recurrence-free survival of patients with
colon cancer, Cox correlation analyses were performed.
Univariate analysis revealed that Differentiation (p =
0.038), American Joint Committee on Cancer (AJCC)
stage (p = 0.002), Distant metastases (p = 0.000), and
Extranodal tumor deposits (p = 0.000) had a significant
influence on OS, while carcinoembryonic antigen (CEA)(p = 0.015) and DMRN level (p = 0.030) had significant
prognostic value for RFS. Further multivariate analysis,
however, revealed that Distant metastasis (M0 vs. M1,
hazard ratio (HR) =7.431, 95% confidential intervals
(CI): 3.864-14.291, p = 0.000) and CEA (normal vs. ele-
vated, HR = 4.144, 95% CI: 1.311-13.099, p = 0.015) were
the only independent prognostic variables for OS and
RFS, respectively (Table 2). This result implied that
tissue-resident nTregs especially in normal tissue adja-
cent to tumor nests may have a negative role on anti-
tumor effects; however, these influences might be limited
and become complicated when their overall impacts on
patient survival are studied.
Discussion
Epigenetic DNA methylation-based diagnostics represent
a new research tool, offering various advantages over
traditional methods [35]. In our study, the FOXP3-TSDR
demethylation status could be accurately monitored and
the exact proportions of nTregs in tissue samples could
be estimated with high sensitivity using this MS-qPCR
system. In addition, when compared to IHC, FCM, and
TMA, it is far less complicated and expensive, and it can
be readily applied to large numbers of archival or frozen
specimens, including blood, tissue, and stool samples [35].
Using the FOXP3-TSDR demethylation assay, Wieczorek
et al. [4] measured the nTreg proportions (DMR) in the
peripheral blood of patients with CRC tumors (n = 27)
and in that of healthy donors (n = 20); however, no signifi-
cant difference was found (2.3% vs. 1.4%, p = 0.068). In
formalin-fixed, paraffin-embedded (FFPE) tissue samples,
significantly higher DMR was noted in tumor tissues of
patients with CRC (n = 15) than in the adjacent normal
colonic mucosa (n = 10) (6.3% vs. 1.5%, p < 0.001). This
was a pilot study aimed at investigating the proportion of
Table 1 Relationships between the TSDR-DMRs and the clinicopathological features of patients with colon cancer
Clinicopathological variables N DMRT (%) DMRN (%) DMRT/DMRN
Mean rank p value Mean rank p value Mean rank p value
Gender Male 78 61.33 0.122 56.72 0.001* 73.59 0.003*
Female 52 71.76 78.66 53.37
Age (years) ≤60 49 57.32 0.054 64.21 0.762 60.98 0.287
>60 81 70.45 66.28 68.23
Maximum Size (cm) ≤5 93 64.68 0.693 66.60 0.599 64.74 0.716
>5 37 67.57 62.74 67.41
Locationa Left side 62 59.76 0.097 62.07 0.322 64.48 0.769
Right side 68 70.74 68.63 66.43
Differentiation G1-G2 87 68.45 0.204 66.78 0.581 65.34 0.947
G3-G4 43 59.53 62.91 65.81
Mucinous or signet-ring carcinoma No 103 67.98 0.701 64.97 0.754 66.53 0.541
Yes 27 64.85 67.52 61.56
CEA Normal 59 58.58 0.056 58.43 0.051 64.86 0.859
Elevated 71 71.25 71.37 66.04
Tumor (T) stage T1-2 20 64.84 0.640 64.82 0.631 64.46 0.460
T3-4 110 69.13 69.23 71.23
Nodal (N) status N0 63 66.97 0.216 65.76 0.275 68.72 0.595
N1-2 66 62.32 64.93 58.50
Distant metastases (M)b M0 101 65.20 0.865 61.26 0.017* 69.18 0.037*
M1 29 66.55 80.26 52.67
AJCC stage I-II 59 64.54 0.754 66.37 0.776 61.56 0.198
III-IV 71 66.62 64.48 70.09
Lymphovascular invasion No 89 66.97 0.513 65.76 0.906 68.72 0.150
Yes 41 62.32 64.93 58.50
Perineural invasion No 109 65.61 0.939 64.28 0.398 67.35 0.202
Yes 21 64.93 71.86 55.90
Extranodal tumor deposits No 107 65.83 0.831 65.08 0.786 66.34 0.585
Yes 23 63.98 67.43 61.61
*A two-tailed p value ≤0.05 was considered statistically significant. Normality tests revealed that none of the data for these three variables (DMRT (%), DMRN (%),
and DMRT/DMRN) were normally distributed; thus, the statistical analyses were performed using nonparametric Mann-Whitney U tests.
aThe left side of the colon consists of the recto-sigmoid junction, sigmoid colon, descending colon, and splenic flexure. The right side of the colon consists of the
cecum, ascending colon, hepatic flexure, and transverse colon.
bIn this study, we included patients with resectable primary lesions. Patients who had distant metastases that were either resectable or unresectalbe were included.
Abbreviations: DMRT, demethylation rate in tumor tissues; DMRN, demethylation rate in normal tissues; CEA, carcinoembryonic antigen; AJCC, American Joint
Committee on Cancer (AJCC).
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marker; however, no valuable prognostic conclusions
could be made due to the statistical power. With a larger
sample size, our data reinforced the feasibility of nTreg
identification utilizing this de novo strategy in CRC-
related research.
When compared to nTregs, an extremely low DMR
was detected among six CRC cell lines in the present
study (Figure 2A). By using MS-qPCR, Lucas and col-
leagues analyzed the FOXP3i1 (TSDR) demethylation
status in various cells lines of malignant carcinomas, in-
cluding CRC, Non-small cell lung cancer (NSCLC), andmelanoma. They found that none of the seven CRC cell
lines and most of the other lines mentioned above con-
tained a substantial level of demethylated FOXP3-TSDR
[19]. Baron and colleagues also confirmed this differential
demethylation status of TSDR between nTregs and other
blood cell subtypes as well as various non-hematopoietic
tissues [14]. CRC cell lines did show detectable FOXP3
mRNA signals, although their levels were extremely low
when compared to nTregs (Figure 2B). We could not ex-
clude the possibility of that FOXP3 might also function as
a potential transcriptional suppressor of oncogene in CRC
cells as in breast cancer cells [36-38] and prostate cancer
Figure 5 Clinical survival analysis according to the levels of TSDR-DMR in different tissue samples. Essentially, patients with lower DMRs,
both in tumor samples (Figure 5A, 5D) and normal samples (Figure 5B, 5E), tended to have better survival when compared to patients with
higher DMRs. However, the difference was significant only for RFS according to the variable DMRN (Figure 5E, p = 0.022). And no significant
difference was found either for OS (Figure 5C) or for RFS (Figure 5F) according to the variables of relative TSDR demethylation level (DMRT/
DMRN). DMRs were classified as high or low in relation to the median values for each (see Additional file 1: Tables S1 and Additional file 2:
Table S2). Log-rank (Mantel-Cox) tests were performed for the overall comparisons. Reference lines within the graphs indicate the 5th year and
3rd year for OS and RFS, respectively.
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sion appears widespread in normal epithelia [41] and ma-
lignant cells, such as glioblastoma [42], ovarian cancer
[43], NSCLC [44], or advanced gastric cancer [45]. It was
also found both in CRC cells in vivo [46] and in colon can-
cer cell line CaCo2 [47], HCA 2.6 and HCA 3.2 [48]
in vitro. Obviously, however, the concerns fell out the
scope of this study, in which our focus was on the expres-
sion levels of FOXP3-TSDR and regarding it as a surrogate
marker for identification pericancerous infiltrating nTregs.
The range of DMR calculated in the present study
using the SYBR Green method was similar to that de-
scribed in reports by Wieczorek et al. [4], in which
sequence-specific probes were adopted in an MS-qPCR
system. Additionally, the relative demethylation levels in
the present study (DMRT/DMRN, median: 2.35) were
comparable to that reported by Salama et al. (FOXP3+
TT/FOXP3
+ TN, median: 2.64), which was evaluated byIHC in TMA samples [30]. This consistence indicated a
similar ratio of the nTregs (demethylated TSDR status)
with Tregs (FOXP3+) in tumor tissues versus normal tis-
sues. However, one of the shortage in this study was the
unavailability of the DMR data of colonic mucosa from
the normal controls, like the others [4]. Further work
might be required to judge the differential TSDR-DMR
expression among tissues from healthy volunteers,
tumor and the corresponding normal tissues from pa-
tients with CRC.
Tregs found at tumor sites contain thymus-derived
nTregs and iTregs converted from CD4+CD25− T cells.
Their accumulation may be due to the proliferation
of pre-existing Tregs in the tumor microenvironment,
the recruitment of Tregs from periphery, and the de
novo conversion of tumor-infiltrating CD4+ lymphocytes
into iTreg [25,49,50]. Our results (Figure 3) were in
agreement with previous reports that significantly more
Table 2 Cox analysis of the prognostic variables on the overall and recurrence-free survival in patients
Prognostic variable Overall survival Recurrence-free survival
P value HR (95% CI) P value HR (95% CI)
Univariate analysis
Gender, Male/Female 0.342 1.357 (0.723-2.550) 0.301 0.602 (0.230-1.576)
Age, ≤60/>60 years 0.494 0.802 (.425-1.510) 0.607 0.787 (.315-1.963)
Maximum Size, ≤5/>5 cm 0.321 1.394 (0.724-2.683) 0.700 1.207 (0.463-3.149)
Location, Left side/Right side 0.129 1.649 (0.864-3.145) 0.365 1.557 (0.597-4.062)
Differentiation, G1-G2/G3-G4 0.038* 1.959 (1.039-3.694) 0.807 0.891 (0.354-2.245)
Mucinous or signet-ring carcinoma, No/Yes 0.684 0.851 (0.391-1.851) 0.354 0.557 (0.162-1.918)
CEA, Normal/Elevated 0.054 1.874 (0.990-3.547) 0.015* 4.144 (1.311-13.099)
Tumor (T) stage, T1-2/T3-4 0.061 0.256 (0.062-1.064) 0.920 0.927 (.210- 4.085)
Nodal (N) status, N0/N1-2 0.504 0.807 (0.430-1.514) 0.121 2.140 (.818- 5.598)
Distant metastases (M), M0/M1a 0.000* 8.412 (4.332-16.338)
AJCC Stage, I-II/ III-IV 0.002* 3.155 (1.533-6.490) 0.551 0.762 (.312-1.860)
Lymphatic/vascular invasion, No/Yes 0.268 1.440 (0.755-2.746) 0.455 0.691 (0.263-1.821)
Perineural invasion, No/Yes 0.354 1.444 (0.664-3.142) 0.085 0.168 (0.022-1.275)
Extranodal tumor deposit, No/Yes 0.000* 4.341 (2.216-8.504) 0.236 2.126 (0.611-7.399)
DMRT level, Low/High 0.493 1.246 (0.664-2.339) 0.070 2.320 (0.934-5.761)
DMRN level, Low/High 0.153 1.588 (0.843-2.994) 0.030* 2.709 (1.102-6.662)
DMRT/DMRN, Low/High 0.884 1.048 (0.558-1.967) 0.876 0.926 (0.353-2.431)
Multivariate analysis
Distant metastases (M), M0/M1 0.000* 7.431 (3.864-14.291)
Differentiation, G1-G2/G3-G4 0.518 1.250 (0.635-2.459)
AJCC Stage, I-II/III-IV 0.885 1.074 (0.406-2.846)
Extranodal tumor deposit, No/Yes 0.330 1.479 (0.673-3.248)
CEA, Normal/Elevated 0.015* 4.144 (1.311-13.099)
DMRN level, Low/High 0.286 1.733 (0.631-4.755)
*A two-tailed p value ≤0.05 was considered statistically significant.
aFor Cox correlation analysis, non-stage IV colon cancer were included for RFS study, so this variable was not selected for analysis.
Abbreviations: HR, hazard ratio; CI, confidential intervals; CEA, carcinoembryonic antigen; AJCC, American Joint Committee on Cancer (AJCC); DMRT, demethylation
rate in tumor tissues; DMRN, demethylation rate in normal tissues.
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corresponding adjacent normal mucosa [27,28,30]; and
our data reinforced the fact that a majority of these sup-
pressive Tregs are functional nTregs [51].
Our data indicated that a higher level of tissue-
resident nTregs infiltration, especially into normal tis-
sues adjacent to tumors (higher DMRN), was correlated
with worse clinicopathological features (distant metasta-
ses) (Figure 4). Higher DMRs also tended to be associ-
ated with a shortened survival time, although only RFS
differences in DMRN were found to be significant after
overall comparisons (Figure 5E). Our findings regarding
the influence of nTregs on patients with CRC are par-
tially in agreement with previously findings [27-30]; But
others also reported different conclusions [31-34]. Al-
though the reasons for these discordant results remain
unclear, the adaptive immune response is thought toplay an important and complicated role in promoting or
suppressing the progression of CRC [30].
Salama et al. [30] were the first to report the prognos-
tic significance FOXP3+ Tregs in normal colonic mu-
cosa from patients with CRC. One of their remarkable
findings was the opposite prognostic significance of high
densities of FOXP3+ Tregs in tumor tissues (better sur-
vival) and in adjacent normal mucosa (worse survival).
Partially in agreement with their findings, our data also
indicated that higher levels of nTregs in normal colonic
mucosa (Higher DMRN), but not in tumor nests, were
significantly correlated with worse clinical features.
FOXP3+ nTregs in normal tissues might have a negative
effect on the anti-tumor response, thus explaining their
association with worse prognosis [30]. However, this asso-
ciation was found to be significantly opposite after tissue
normalization (DMRT/DMRN) (Table. 1). This statistical
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of mean ranks in DMRT than that in DMRN, and no
meaningful clinical interpretation could be made under
this situation.
Correale P et al. [31] also reported that patients with
reduced intraepithelial CD3+ T-cell densities in the
tumor had reduced disease-free survival times (DFS)
(HR: 1.87; 95% CI: 1.10, 3.16; p = 0.018). However, the
intraepithelial FOXP3+ cell density in tumor nests was
not prognostic. In the present study, univariate survival
analysis confirmed that certain conventional histopatho-
logical markers were related with poor survival out-
comes, including OS and RFS (Figure 5, Table 2). Only
DMRN was found to be a prognostic variable for RFS in
patients with non-stage IV colon cancer by univariate
analysis; however, it failed to be an independent factor
after multivariate analysis. This result may be partially
attributed to sampling errors, and further investigation
might be required.
Nishikawa et al. concluded that, in CRC, the obvious
prognostic contradiction associated with FOXP3+ Treg
infiltration might be attributed to the different composi-
tions of FOXP3+ T-cell subpopulations in altered tumor
types and tissue sites [52]. FOXP3+ T cells infiltrating
into colon cancers contain higher frequencies of effector
nTreg cells (CD45RA−FOXP3hiCD25hi) as well as non-
Treg cells (CD45RA−FOXP3loCD25lo)20. The latter ones
are capable of secreting pro-inflammatory cytokines
[15,53,54], which could contribute to the improved prog-
nosis of some patients with colon cancer even when high
densities of total FOXP3+ T cells are present. Terzic
et al. proposed the hypothesis of a septic microenviron-
ment in colon cancer. By suppressing the inflammation
and immune responses resulting from bacterial invasion,
FOXP3 + Tregs could in fact be anti-tumorigenic [55].
Further functional studies of Tregs in tumor and adja-
cent normal tissues may be required to discover their
exact role in the antitumor response.
Regarding gender, our data were consistent with the
previous study. Sinicrope et al. [28] also detected higher
levels of intratumor FOXP3 expression in female pa-
tients with CRC. Wieczorek et al. [4] reported similar
results of slightly higher TSDR-DMR in female healthy
controls versus male healthy controls. In female patients
or healthy controls, one of the two FOXP3-TSDR alleles
is methylated as a result of X-inactivation [5,56]. This
might partially explain the gender difference or bias in
TSDR-DMR when corrected with a factor of 2. However,
there is no exact explanation for these findings, and fur-
ther investigation is required.
Conclusions
In conclusion, the FOXP3-TSDR demethylation status
could differentiate nTregs from non-nTregs, suggestingthat this epigenetic status might be a promising surro-
gate biomarker for the identification of nTregs in clinical
research when using archival CRC samples. A signifi-
cantly higher TSDR-DMR and FOXP3 mRNA as well as
protein expression level were found in tumor sites versus
normal ones, implying that abnormal recruitment of
nTregs occurred at tumor sites. A higher FOXP3-TSDR
DMR in adjacent normal tissues, but not in malignant
tissues, was found in patients with distant metastases;
this was also associated with worse recurrence-free sur-
vival. Further analysis indicated that nTregs might have
a negative role in anti-tumor effects, although their im-
pacts on the survival outcomes may be limited and
complicated.
Methods
Patient population, tissue samples, and clinicopathological
variables
A total of 130 colon carcinoma samples were obtained
after approval was granted by the Medical Ethics Com-
mittee of Fudan University Shanghai Cancer Center.
Samples were retrieved from consecutive, surgically
treated patients (78 males and 52 females with stage I-
IV colon cancer) between January and December 2008.
In this study, only patients who underwent colectomy
for colon cancer without chemotherapy or radiotherapy
before surgery were selected, no matter their TNM stage.
Differentiation grading and TNM classification for colon
cancer were confirmed according to the criteria described
in the AJCC Cancer Staging Manual (7th edition, 2010).
Fresh colon tumor tissues coupled with corresponding
normal colonic tissues were obtained immediately after
surgery, washed twice with chilled phosphate-buffered sa-
line (PBS), immediately stored in liquid nitrogen, and kept
at -80°C in our tissue bank for further use.
The patients’ electronic medical records were reviewed.
Various clinicopathological variables were investigated.
Clinical survival outcomes, including OS and RFS, were
also studied. In this study, OS was calculated from the
time when the patient was diagnosed until their death
from any cause; for a non-stage IV patient with R0 resec-
tion, RFS was computed from the time when the patient
was diagnosed to the first evidence of recurrence or me-
tastasis. The last follow-up date was set as Dec 31, 2013.
Isolation of PBMCs, purification of nTregs, and
differentiation of iTregs
Human primary cell isolation and culture were per-
formed as described previously [57,58]. Briefly, PBMCs
were isolated by Ficoll-Hypaque (Seromed, Biochrom
KG, Berlin, Germany) from buffy coats of healthy male
blood donors at the Shanghai Blood Center. nTregs were
separated with a FACSAria II cell sorter (BD Biosciences,
USA) using the monoclonal antibodies anti-CD4-FITC,
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were gated from a population of CD4+ CD25- effector T
cells and separated with anti-CD45RA-Percp-CY5.5 (all
from BD Biosciences, USA). Induced Tregs (iTregs) were
induced from naïve T cells with recombinant TGF-β
(5 ng/ml) and IL-2 (100 U/ml). The purified human
nTregs and iTregs were expanded with anti-CD3/CD28
beads (Invitrogen, USA) and 500 U/ml IL-2 (R&D, USA).
Both cell types were cultured with X-VIVO 15 medium
(Lonza, Cologne, Germany) supplemented with 10% heat-
inactivated human AB serum (Irvine Scientific, USA), 1%
GlutaMax, and 1% NaPyr (Both from GIBCO, Life
Technologies, USA). Cell fraction purity was deter-
mined using intracellular FOXP3 staining with FOXP3-
PE-A (eBioscience, USA), following the manufacturer’s
instructions. FACS data were then analyzed using FlowJo
software (Tree Star, USA).
Other cell Lines and cell culture conditions
HEK293T cells and six human colorectal cancer cell
lines (RKO, Colo-320, LS-174T, SW480, SW620, and
HCT 116) were utilized. All lines were obtained from
the Type Culture Collection of the Chinese Academy of
Sciences (Shanghai, China) within 6 months, where they
were characterized by cell vitality detection, DNA finger-
printing, mycoplasma detection, and isozyme detection.
The RKO, LS-174T, and HCT 116 cell lines were cul-
tured in DMEM medium; the Colo-320 line was cul-
tured in RPMI-1640 medium; and the SW480 and
SW620 lines were cultured in L-15 medium. All media
contained 10% FBS, and all media and FBS were pur-
chased from GIBCO® (Life Technologies, USA).
Genomic DNA isolation, bisulfite conversion, and MS-qPCR
Genomic DNA (gDNA) was isolated using DNA isolation
kits (ZYMO Research, USA). For cell and tissue samples,
the protocols for cultured cells or solid tissues were
followed, respectively. Bisulfite treatment of 0.5-1 μg gen-
omic DNA was performed using methylation kits (ZYMO
Research, USA) according to the manufacturer’s ins-
tructions. MS-qPCR was performed using SYBR Green
reagent (Thermo Scientific, USA). Primers for methylation-
specific and demethylation-specific FOXP3 were designed
using MethPrimer [59]. Real-time PCR was performed in
a final reaction volume of 10 μL using the ABI Prism
7900T Sequence Detection System (Applied Biosystems,
USA), containing 25 pmol each of methylation or
demethylation-specific forward and reverse primers for
FOXP3-TSDR and 25-50 ng of bisulfite-treated gen-
omic DNA template. Cycling conditions and primers for
TSDR are listed (see Supplementary Information, Additional
file 3: Table S3).
The demethylation rate (DMR) of FOXP3-TSDR was
computed using a formula described previously [60,61]:100/[1 + 2(CtTG- CtCG)] × 100%, where CtTG represents
the cycle threshold achieved with TG (demethylated)
primers and CtCG represents the cycle threshold
achieved with CG (methylated) primers. For female pa-
tients, this rate was corrected by a factor of 2 because
one of the two TSDR alleles is methylated as a result of
X inactivation [5,56,60,61].
RNA isolation, reverse transcription, and real-time qPCR
Total RNA was isolated from cultured cell lines or tissue
samples using the TRIzol® Reagent (Life Technologies,
USA) according to the manufacturer's instructions. RNA
was quantified, and complementary DNA (cDNA) was
reverse transcribed with the RT reagent kit (Takara,
Japan) according to the manufacturer's protocol. RT-
PCR was performed using the SYBR Green reagent
(Thermo Scientific, USA). For quantitative PCR, 5 ng of
the RT reaction was used in a 10-μL reaction volume,
and amplification was performed using the ABI Prism
7900T Sequence Detection System. The cycling con-
ditions and primers for amplification of β-actin and
FOXP3 are listed (see Additional file 3: Table S3). RT-
PCR products were verified by DNA sequencing. DL500
(Takara Bio Inc., Japan) was used as DNA marker for
agarose gel electrophoresis.
Tissue homogenization, lysis, and Western blotting
Tissue samples (approximately 130-150 mg) were lysed
at 4°C using a homogenizer (Precellys™ 24, Bertin,
France) in 2-mL tubes prefilled with magnetic beads and
RIPA lysis buffer (1 mM Na3VO4, NaF, PMSF and 1%
protease inhibitor cocktail [Thermo Scientific, USA]).
After measurement of the protein concentration using
the BCA Protein Assay Kit (Thermo Scientific, USA),
protein samples (60-80 μg) were loaded and separated
on 10% acrylamide gels for SDS-PAGE. Subsequently,
the proteins were transferred to 0.25-μm PVDF mem-
branes. The membranes were then incubated with a
mouse monoclonal antibody against human FOXP3
(ab22510, Abcam, USA) at a concentration of 4 μg/mL
(1:250) overnight at 4°C. An anti-GAPDH mouse anti-
body was simultaneously used as a loading control
(1:2000 dilution; Suji-tech, Beijing, China). Then, the
membrane was incubated with an HRP-conjugated sec-
ondary antibody (1:5000 dilution, Suji-tech, Beijing,
China) for 1 hour at room temperature. All blots were
visualized using an ECL Western Blotting Substrate
(Thermo Scientific, USA) and were quantatively analyzed
by ImageJ 1.46 (National Institute of Health, USA) [62].
Statistical analysis
Normality tests were performed to tests whether the
data were normally distributed. Median values of the
DMRs were adopted as cut-off points to define low or
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factors were determined using Cox regression analysis.
Kaplan–Meier curves were used to assess the influence
of the TSDR demethylation status on OS and RFS. The
differences were tested using the log-rank test. Statistical
analyses were performed using SPSS v.20.0 (IBM Corp.,
USA). A two-tailed p-value lower than 0.05 was consi-
dered statistically significant.
Consent
Written informed consents were obtained from the pa-
tients for the publication of this report and any accom-
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